Berenberg Bank reissued their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a report published on Monday, Marketbeat.com reports. The brokerage currently has a £150 ($197.24) price objective on the biopharmaceutical company’s stock.
Several other research analysts have also issued reports on AZN. JPMorgan Chase & Co. reissued an overweight rating on shares of AstraZeneca in a research report on Tuesday, June 4th. Jefferies Financial Group increased their target price on AstraZeneca from GBX 71 ($0.93) to GBX 74 ($0.97) and gave the stock a hold rating in a research report on Tuesday, July 2nd. Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Thursday, July 25th. Citigroup reissued a buy rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Finally, Deutsche Bank Aktiengesellschaft reissued a hold rating and issued a £110 ($144.64) target price on shares of AstraZeneca in a research report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of £105.53 ($138.77).
Read Our Latest Research Report on AZN
AstraZeneca Trading Down 3.9 %
AstraZeneca Cuts Dividend
The business also recently declared a dividend, which will be paid on Monday, September 9th. Investors of record on Thursday, August 8th will be paid a GBX 77.60 ($1.02) dividend. The ex-dividend date is Thursday, August 8th. This represents a dividend yield of 0.64%. AstraZeneca’s payout ratio is currently 7,500.00%.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
- Five stocks we like better than AstraZeneca
- What is the Dogs of the Dow Strategy? Overview and Examples
- Emerging Markets: What They Are and Why They Matter
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Recession or Not, These 3 Stocks Are Winners
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.